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Abstract: In this review, we discuss an immunological-driven sign termed the Completed 
Self, which is related to a holistic determination of health vs. disease. This sign (human 
plus commensal microbiota) forms the human superorganism. The worldwide emergence 
of an epidemic of chronic diseases has caused increased healthcare costs, increased 
premature mortality and reduced quality of life for a majority of the world’s population. In 
addition, it has raised questions concerning the interactions between humans and their 
environment and potential imbalances. Misregulated inflammation, a host defense-
homeostasis disorder, appears to be a key biomarker connecting a majority of chronic 
diseases. We consider the apparent contributors to this disorder that promote a web of 
interlinked comorbid conditions. Three key events are suggested to play a role: (1) altered 
epigenetic programming (AEP) that may span multiple generations, (2) developmental 
immunotoxicity (DIT), and (3) failure to adequately incorporate commensal microbes as a 
newborn (i.e., the incomplete self). We discuss how these three events can combine to 
determine whether the human superorganism is able to adequately and completely form 
during early childhood. We also discuss how corruption of this event can affect the risk of 
later-life diseases. 
Keywords: chronic diseases; inflammation; patterns of comorbidities; developmental 
immunotoxicity; commensal bacteria; microbiome; superorganism; biosemiotics; sign; 
mucosal tissues 
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1. Introduction 
In this review of early-life development and its impact on health vs. disease, we present the tenet 
that the newborn human naturally engages in an immunologically-permitted merger with designated 
parts of the environment. This merger reflects where the infant has been both genetically and 
epigenetically and where the infant will be going in terms of a future health trajectory. The infant-
environment merger also represents a significant biological sign. An effective merger provides for an 
optimized interaction between the environmentally-enhanced infant and the outside world. In contrast, 
corruption of this merger results in a life course of increased risk of disease. Much of this review will 
discuss the nature of this merger as a biological sign and how this key event affects the definition of 
immunologically-defined self, biological integrity and risk of later-life disorder and disease. 
1.1. Signs, Biomarkers, and Health Outcomes 
In the search for one or more signs that represent a crossroads of health vs. disorder and disease, we 
searched for a significant human health risk/benefit and a defining biomarker connected to this health 
outcome. This led us to focus on the health risk of chronic noncommunicable diseases (NCDs). We 
then identified the functional biomarker (i.e., useful frame of reference) most closely affecting chronic 
diseases. In this case, the biomarker that most consistently connects the individual to chronic diseases 
is: misregulated inflammation [1–4]. The importance of misregulated inflammation as a frame of 
reference is further supported by the focus of Davidson and Seneff [5] in their review article appearing 
in this same special issue on biosemiotics. Effectively regulated inflammation in tissues is connected to 
effective host defense and good health, while misregulated inflammation leads to pathology and 
chronic disease. We then searched for one or more signs that connect regulated vs. misregulated 
inflammation to health vs. chronic disease employing immune system-based surveillance as a 
framework, since it has been previously employed for similar purposes [6].  
Our initial focus was on signs connected to proper vs. misregulated inflammation focusing on 
developmental immunotoxicity and epigenetic programming. However, it became apparent that using a 
different frame of reference would produce an even more holistic sign that could connect inflammation 
to chronic diseases. That different frame of reference began with the most basic question: what 
constitutes a fully-formed human individual? The answer is that a fully-formed human is far more than 
what is encoded by the human genome [7]. The fully-formed human contains more microbial DNA 
than actual human DNA  and  is connected to the environment in a way that helps to both define and 
sustain the completed human [8]. Furthermore, alteration of the human microbiome appears to be just 
as likely to result in chronic disease as does alteration of key developing human eukaryotic cells  
(e.g., immune cells) [9]. The paradigm we present is one in which microbial-human symbiotes are the 
basic composite human that is needed for optimized, effective lifelong health. The fundamental sign 
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we seek is likely to be connected to this more complete individual that has also been termed the  
human superorganism [10].  
This review: (1) Justifies the focus on chronic diseases and conditions as the principle out-picturing 
of human disorder. (2) Details the identification of misregulated inflammation as a signal for chronic 
diseases. (3) Introduces and discusses the concept of the Completed Self as a useful sign for health vs. 
chronic illness. (4) Details the process of human-microbial symbiotic formation in the neonate, and  
(5) Considers the impact of altered epigenetic programming (AEP) and developmental immunotoxicity 
(DIT) on formation of the human superorganism and/or expression of the full completed self phenotype. 
1.2. Development of Self Identity from an Immunological Perspective 
One of the first important questions is: who are we immunologically? Historically, there has been a 
perspective in immunology that the human genome encodes us and in order to have integrity and 
fidelity, our immune system must protect us from everything else (i.e., the environment). Specialized 
immune cells such as alveolar macrophages, skin dendritic cells and gastrointestinal-associated lamina 
propria dendritic cells reside at the portals of exposure to the environment for the purpose of sampling 
the environment and helping to protect us from potential danger. But more recently, an expanded view 
of humans that includes a significant microbial super-genome has been proposed as a  
fundamental concept [11].  
Studies suggest that when the immune system only sees and tries to defend what is encoded 
exclusively by the host mammalian genome, it is highly dysfunctional, less effective in maintaining 
homeostasis, and less well prepared to defend the host from the adverse outcomes of pathogenic 
challenge [12–14]. An updated view of self-identity is that a mammalian genome-encoded organism 
completely separate from the environment is disordered, dysfunctional in self-recognition, and more 
likely to have problems protecting the host from serious environmental challenge. 
As pointed out by Oller [6], major histocompatibility complex (MHC) expression is a critical 
component in defining what is self from non-self. We tolerate self and attack, kill, expel or wall off 
what is non-self. Proteins expressed by MHC genes provide a translator system for identifying cells 
and proteins that belong to us from those that are intrusive and/or dangerous. At least for years that is 
what seemed like the essential paradigm for self-identity. But recent research has shown that the 
boundaries of what constitutes self have been dramatically blurred from traditional thinking. The 
reason an immune definition of self is important is that our bodies act to protect or defend the 
boundaries of self. Viruses, pathogenic bacteria, or significantly aberrant cells (e.g., cancer cells) do 
not meet the criteria of self.  
The traditional view indicates that host proteins and cells are the primary targets of self recognition 
such that anything else would be seen as foreign and subject to host defense responses. But this is 
actually not a holistic view of what is immunological self.  
From childhood on, we are reliant on more than a trillion microbes that inhabit our gut, airways, 
skin, oral cavity, conjunctiva, and urogenital tract. These form what has been termed the microbiota 
with genetic components of these microorganisms known as the microbiome. In fact, if the human 
genome was underwhelming in terms of the number of genes identified vs. the number that had been 
expected, our commensal microbes have at least five times that number of genes. In other words, we 
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are carrying far more microbial genes than our own composed DNA. These microbial genes and 
organisms not only carry out their own metabolism, they are specifically tailored to our bodies based 
on our own individual characteristics. Each individual has both a unique fingerprint as well as a 
somewhat unique microbial signature. 
A very minute portion of the human life span is reliant solely on personal, DNA-encoded protein 
products. This time period encompasses a few minutes surrounding birth, after which humans become 
reliant on a combination of personal DNA-encoded proteins as well as those of the microbiota that 
complete the human superorganism. Yet, as incomplete as a newborn infant is and as quickly as they 
must begin acquiring microbiota from their environment, impacts to this biologically-interconnected 
path can begin even before birth.  
1.3. Prenatal Symbiosis  
Prenatal development can be viewed as a symbiotic relationship between mother and fetus. One 
point made by researchers who embrace this view is that the placenta is developed by the mother and 
child in combination and possesses both maternal and fetal parts [15–17]. Additionally, the placenta 
has a certain plasticity, can sense the maternal fetal environment and responds dynamically to a 
changed environment [18]. Oller [6] discussed the fact that via the placenta, the “newly forming 
individual” is afforded with both immunological protection and nutrients as well as safety from 
potentially harmful effects of the mother’s own immune system. 
As described by Martin et al. [19], the fetal immune system develops in a tight symbiotic and 
protected relationship with the mother in utero [20]. While the various cell types and components 
needed for immune function begin to emerge early in development, functional capacity is reduced 
particularly for those immune functions that would jeopardize the pregnancy and development of the 
embryo to full term [21]. This reduction occurs not only in the fetus but also in the mother as specific 
immune strategies protect against improper cell mediated and immune inflammatory responses. 
Carefully orchestrated control of regulated functional levels that are tailored to the stage of the 
pregnancy are needed to ensure fetal survival [22]. 
Several lines of evidence support this synchronized dual restriction of the mother’s and fetus’ 
immune capacities. The fetus develops successfully in what is largely a T helper 2 (Th2) preferred 
environment [23,24]. Th2 skewing of the immune function in the mother causes chronic diseases that 
are Th2 driven (e.g., systemic lupus erythematosus) to be exacerbated while Th1-associated disease 
symptoms (e.g., rheumatoid arthritis) are often lessened [25]. Additionally, women with recurrent 
miscarriages [26] or who experience preterm labor [21] generally fail to down-regulate their Th1 
responses particularly at the maternal-fetal interface. They also have improper control of inflammatory 
cytokine levels at the placental interface [27]. 
1.4. Birth Delivery as the Transition 
Historically, we have viewed birth as the critical transition from sheltered protection to a largely 
complete individual. If Th1 dampening and controlled inflammations are needed to immunologically 
maintain the symbiotic mother-fetus relationship, then parturition has different requirements. In effect, 
it is a dissociation of the symbiosis. In fact, there is evidence in animal models that macrophage 
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activation and an inflammation-like process is needed to initiate the events surrounding birth [28,29]. 
Shynlova et al. [30] described how proinflammatory cytokine-activated immune cells infiltrate the 
uterus and initiate labor. 
Certainly, maturation must continue after birth and does for many physiological systems until at or 
near adulthood [31−33]. But having a fully-formed yet immature organism is completely different 
from having an organism that may be born incomplete and needs to add external components to be 
completed. It is this latter concept that is probably closer to reality given what we now know about 
microbial symbiosis. We will argue precisely the view that our microbiome is needed to complete us. 
2. Results  
2.1. The Completed Self Concept 
Several investigators have suggested that it is more accurate and potentially useful to think of 
mammals as “superorganisms” composed of both mammalian and microbial cells, which are 
exquisitely interlinked to affect health [34,35]. No longer does our human-driven core constitute our 
Completed Self. Instead, as stated by Sleator [36], humans are more likely to be “a collective of human 
and microbial cells all working for the collective.” In actuality, we are multiple organisms when we 
exist as individuals free of our mother’s womb. Zhu et al. [37] termed the human gut microbiome as 
the “second human genome” and pointed to the fact that microbial genes outnumber human genes by 
150 fold. Recently, Murdoch and Detsky [38] suggested healthcare needs to shift away from the 
traditional focus on just human physiology to a focus on the human superorganism. While the immune 
system is known to play the critical role of homeostasis in tissues, Eberl [39] argued that its principle 
role is not necessarily as a killer but as a homeostatic regulator of the human superorganism.  
 In our view of the Completed Self, we will argue that this is a paramount sign or signal determining 
health vs. disease. The focus of this paper is on chronic diseases as the most significant category of 
diseases. But, if self-completion is a key sign, there are many prenatal and perinatal factors that affect 
whether self-completion can occur successfully in the infant. These factors are illustrated in Figure 1 
along with a developmental timeline. 
2.2. Sources of Microbiota for Infant Self-Completion 
Introduction to a useful environment is among the most important considerations for the newborn, 
and the perinatal period is the most critical for acquisition of commensal microbes and completion of 
the self. While most of the attention is centered on birth and the neonatal period of microbial 
colonization, some investigators suggest that attention should be paid to maternal microbes including 
those at the maternal-fetal interface [40]. For example, differential prenatal fetal T cell priming and 
newborn levels of the cytokine interleukin-12 (IL-12) have been reported based on whether 
Lactobacillus had colonized the maternal vagina [41]. Therefore, the maternal microbiome is a 
consideration for the baby’s immune system before, during and after birth.  
The newborn emerges from the womb essentially sterile. Microbial colonization of the infant’s gut, 
skin, lungs, conjunctiva and urogenital tract begins almost immediately upon birth. Factors that affect 
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the infant’s microbiota colonization are:  mode of delivery, feeding regime, maternal diet/weight, 
probiotic and prebiotic use and antibiotic exposure pre-, peri- and post-natally [42].  
Figure 1. A timeline for formation of the Completed Self is depicted. Transgenerational 
epigenetics (via prior generations) and perinatal developmental immune processes combine 
with neonatal microbial colonization to establish the parameters of the human-microbiome 
superorganism. There are specific developmental windows for each contributing factor that 
determine whether the Completed Self is appropriately formed in the young child.  
 
The baby’s direct contact with the mother and the environment provides microbial exposure for 
colonization. Additionally, breast milk is an important source of gut microbiota for the infant. 
Urbaniak et al. [43] indicate that breast milk provides the infant with a significant amount and 
diversity of microbes that are lacking in formulas. Even probiotic supplemented formulas lack the 
diversity of bacteria that is provided to the infant via breast milk [43]. Differences in the microbial 
composition of breast milk have been reported. As an example, breast milk from obese mothers was 
found to be less diverse in bacteria than breast milk from non-obese women [44]. 
Colonization of the infant skin microbiota is also important in reducing the risk of later life 
diseases. Nagata et al. [45] found that the newborn’s skin is populated with microbes transmitted 
directly from the mother’s skin. Most of the transitions among commensal skin fungus appear to occur 
within 30 days of birth [45]. In contrast, Capone et al. [46] reported that most of the skin microbiota 
colonization occurs over a longer period during the infant’s first year of life and the bacteria are 
distributed in a site specific manner. 
Comparatively less research has gone into the colonization of conjunctiva, and collection 
methodologies to examine diversity can be challenging. Thus far, results suggest that the normal, 
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healthy conjunctiva also have a significant diversity of different microbes represented [47]. 
Information on critical developmental windows for establishment of the infant’s microbiome is 
generally lacking to date. However, studies have been performed on potentially pathogenic microbes 
detected in premature neonates spending significant time in the neonatal intensive care unit [48]. 
As with conjunctiva, complete characterization of the normal vs. disrupted urogenital microbiota 
has lagged behind that of the gut, and critical windows for neonatal colonization have yet to be 
defined. Analysis of the healthy female genital tract has proved to be a challenge since present results 
suggest there is both significant microbe diversity and site specificity [49].  
2.3. Critical Timing for Self-Completion 
Ironically, the birth process itself may be useful for seeding commensal microbes and helping to 
drive immune maturation and effective balance. Several studies have shown that birth delivery mode 
affects neonatal immune balance. Shortly after birth, vaginally delivered newborns have enhanced 
colonization of certain gut bacteria (e.g., Bifidobacteria sp.)  [50] and a more mature and effectively 
balanced (Th1 vs. Th2) immune system [51] than Caesarean-delivered babies.  
Early-life introduction of commensal microbes appears to be crucial and difficult to correct later in 
life. Significantly, there appears to be a critical postnatal window during which bacterial colonization 
needs to occur to achieve effective mucosal immunity and avoid persistent problems in the adult. In a 
study in piglets, Mulder et al. [52] found that a hard-wiring of both adult gut microbiota and adult 
mucosal immunity occurred based on microbial exposures taking place during the first few days of 
life. They concluded that microbial exposure throughout early life is an important risk factor in the 
development of immune diseases in children. 
2.4. Health vs. Disease: the Epidemic of Chronic Diseases and Conditions 
In the present examination of signs that are linked to health vs. disease, our focus is on chronic 
diseases as the most significant category to represent human disease. One of the remarkable shifts in 
health during the latter portion of the 20th century has been the relative decline in mortality due to 
infectious diseases and its replacement with increased mortality due to non-communicable chronic 
diseases [53]. The Harvard School of Public Health and the World Economic Forum estimated that 
diseases such as diabetes, chronic respiratory diseases, and heart disease presently account for 63% of 
deaths world-wide and are projected to cost 48% of the global gross domestic product by the year  
2030 [54]. The toll of chronic diseases is measured not only in premature death but also in seriously-
challenged lives. Many adverse outcomes involve debilitating conditions that result in rising healthcare 
costs, lost wages, reduced quality of life and increased burdens for families and communities. In fact, 
chronic diseases have been suggested to pose “the single, greatest sustained threat to the stability of 
heath care systems worldwide” [55].  
Rising prevalence of chronic diseases is a priority concern in the United States [56], Europe [57], 
Asia [58], Australia [59], Africa [60], and South America [61]. The situation has become sufficiently 
serious that for only the second time in its history, the General Assembly of the United Nations 
brought a health topic to the floor for debate. The first instance concerned the topic of HIV/AIDS, 
which was discussed over a decade ago. In 2011, the topic was the chronic disease epidemic [62].  
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According to Mayes and Oliver [63], the transition from acute, communicable conditions among 
humans to chronic, noncommunicable conditions represents a massive, gradually developing, global 
crisis. There is concern that governments have been slow to address prevention of chronic diseases in 
keeping with the seriousness of the economic and societal impact. In fact, Mayes and Oliver [63] argue 
that several structural impediments limit much-needed responses. Among these is the fact that public 
health initiatives addressing chronic diseases have benefits that are dispersed and delayed. 
Additionally, when compared with medical treatments designed to manage symptoms of a disease, 
efforts to prevent something bad from happening may appear to be mundane, with both the prevention 
practitioners and their efforts remaining largely invisible [64]. Mayes and Oliver [63] suggested that a 
paradigm shift is needed in which “health in all policies” takes precedence. 
In a recent article on chronic diseases, Freudenberg and Olden [65] posed the following challenge: 
“To lower the incidence of chronic diseases and thus the costs they impose on our society and health 
care system will require addressing the deeper causes of the increase in recent decades.” Table 1 shows 
some examples of health care cost estimates for pediatric chronic diseases.  
Table 1. Healthcare and Other Costs Associated with Chronic Diseases and Conditions in Children. 
Entryway 
Disease or 
Condition 
Population studied Period 
of study 
Category of costs Per annum 
amount per 
patient 
Reference 
Asthma School age children in 
a 1996 Medical 
Expenditure Panel 
Survey 
1996 Total economic 
impact, medical and 
lost parental wages 
$791 [146] 
Asthma 
(difficult to 
control) 
Children 6-12 years of 
age with difficult to 
control asthma from 
several US sites 
2001–
2004 
Total asthma costs: 
medications, physician 
visits, hospital visits; 
lost work/school days 
$7,846 [147] 
Autism 
spectrum 
disorders 
US: Medicaid database 
from 42 states 
2003 Total health care 
expenditures in 
Medicaid per child per 
annum 
$22,079 [148] 
Childhood 
chronic kidney 
disease 
Children from Canada 
(British Columbia and 
Yukon) 
2009 Annual 
pharmaceutical cost 
$1,800 [149] 
Pediatric 
Crohn’s 
disease 
Pediatric patients in 
Canterbury, New 
Zealand 
2010-
2011 
Total (direct and 
indirect) cost per 
person per annum 
$14,375 
NZD 
[150] 
Pediatric  
food allergies 
Children 0–18 years 
of age as one 
categories in the 
study 
 
2007 Mean direct medical 
cost per child per 
annum 
$3,635 [151] 
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Table 1. Cont. 
Entryway 
Disease or 
Condition 
Population studied Period 
of study 
Category of costs Per annum 
amount per 
patient 
Reference 
Kawasaki  
disease 
Across US 1997–
1999 
Median hospitalization 
cost 
$6,169 [152] 
Pediatric  
arthritis 
2nd Children’s Hospital 
at Berlin-Buch cohort 
1998–
2000 
Mean cost per patient 
per annum 
3,500 Euros [153] 
Type 1  
diabetes 
Texas 2004–
2005 
Median direct costs 
per person per annum 
$4,730 [154] 
Apart from the impact on quality of life, the per annum toll that begins in childhood and the 
increasing prevalence of these diseases and conditions provide the basis for more effective prevention. 
In the present review, we argue that three areas of priority could help to address the human burden of 
chronic diseases: (1) avoidance of adverse epigenetic alterations including those with stable 
transgenerational inheritance, (2) improved protection of the developing immune system from 
environmental insult, and (3) strategies to facilitate microbial-human symbiosis in childhood and 
formation of the Completed Self. 
2.5. Chronic Diseases Are Connected as Interlinked Patterns 
While some chronic diseases arise as multi-organ or systemic diseases (e.g., systemic lupus 
erythematosus (SLE)), the majority are directed toward a specific organ, tissue, or physiological 
system (e.g., asthma, inflammatory bowel disease). From a morphogenic viewpoint, cardiovascular 
diseases were seen as distinct from chronic kidney disease or hepatic steatosis, psoriasis had no 
bearing on rheumatoid arthritis, and gastrointestinal allergy or autoimmune thyroiditis had no impact 
on neurological problems. Medical coding of chronic diseases has had a similar effect in which 
conditions that may involve a common dysfunctional basis (e.g., autoimmunity) are viewed more by 
their organ or tissue specific site than by an actual biological categorization [66]. As a result, 
rheumatoid arthritis, psoriasis, inflammatory bowel disease and type 1 diabetes each may be treated by 
different specialists. But in fact, these chronic diseases may be more related than previously suspected. 
Recent findings indicate that these supposedly disparate chronic diseases that target different tissues are 
interlinked both in underlying biological dysfunction as well as in potential comorbid diseases risks [67]. 
The initial concept of interlinked patterns of diseases or conditions did not begin with a 
consideration of immune dysfunction based diseases. Instead, it was a comparatively narrow category 
of male reproductive conditions followed by a larger category of metabolic-dysfunctions that 
suggested the benefits of examining the landscape of chronic diseases and conditions from a more 
holistic perspective. One of the initial characterizations linking chronic diseases and conditions keyed 
to early life environmental conditions was in the area of testicular dysgenesis syndrome [68, 69]. With 
this syndrome, testicular germ cell cancer, cryptorchidism and some cases of hypospadias and male 
infertility have been linked with impaired development of the testis. This was followed by the 
conceptual framework of metabolic syndrome [70] where such interlinked conditions as insulin 
resistance, diabetes, and hypertension were seen as forming a matrix that represented an integrated 
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state of dysfunction. With metabolic syndrome, the interlinked conditions extended beyond a single 
tissue or organ affecting multiple symptoms as well as risk of multiple diseases. 
In a series of papers, Dietert and collaborators applied the concepts of interlinked conditions to the 
identification of larger patterns of immune dysfunction-based, inflammation-driven, chronic diseases. 
The disease terrain that is interconnected via immune dysfunction and inflammatory misregulation is 
remarkably large encompassing many, if not most, chronic diseases and conditions [71−73]. This 
breadth of biological interconnectivity becomes evident with the realization that numerous chronic 
diseases have comorbidities that include one or more of the following: depression, sensory loss 
(including eyesight, hearing and/or sense of smell), frailty, and sleep disorders/problems [67]. 
Recently, specific risk of cancer was included among the immune dysfunction-inflammation based 
patterns [66]. In fact the causative and risk-based linkages among chronic diseases are so extensive 
that in many ways it can be useful to consider them as one or more units of conditions rather than 
myriad diseases.  
2.6. Chronic Disease Patterns Begin Early in Life 
The foundation for risk of chronic disease begins in early life [74–76]. Studies from the past two 
decades have demonstrated that the most critical windows for exposures to chemicals and drugs and 
toxicological risk of chronic diseases are the prenatal, neonatal and juvenile periods of development. 
Much of the original focus of developmental environment and adverse health outcomes was placed on 
prenatal conditions and risk of adult-onset diseases. For example, the developmental basis of adult 
health and disease became established through the “Barker Hypothesis” in which prenatal 
programming was linked with adult offspring cardiovascular disease [77,78]. Since the original 
observations, prenatal environmental programming, including low birth weight, have been associated 
with an elevated risk of such conditions as hypertension [79], insulin resistance [80], diabetes [81], 
atherosclerosis [82], and chronic kidney disease [83] again primarily focused on adult disease.  
However, two key findings extend the prenatal programming-adult relationship to a much broader 
terrain. First, far more environmental factors are known to affect the risk of disease in the offspring 
than just maternal undernutrition. In fact myriad environmental factors ranging from specific dietary 
factors to drugs, chemicals, infections, and physical and psychological stressors are known to operate 
via early development to affect risk of later life disease. Second, it is clear that the impact of fetal 
programming occurs in children. Risk of prominent childhood-onset diseases is equally susceptible to 
fetal programming as is risk of more geriatric-onset conditions. Additionally, the fetal-derived bases of 
diseases like atherosclerosis are already present in children even if disease diagnosis may not occur 
until adulthood [84]. For these reasons, we will argue that the patterns of chronic diseases are already 
in place in children following early-life problematic exposures to chemicals and/or drugs. 
A striking finding is that over half of US children have some form of chronic disease or condition 
and/or developmental delay. A 2011 study by Bethell et al. [85] based on 2007 data, found that 43% of 
US children had at least one of 20 designated chronic conditions. When obesity and developmental 
delays were included as additional inflammation-affected chronic conditions, that percentage was 
elevated to 54%. Almost one fifth of all children had conditions resulting in special health care needs.  
Entropy 2012, 14 2046 
 
 
Cost consideration for chronic diseases come in several forms including direct medical care costs, 
prescription drug costs, and lost income. The effect of adding comorbidities with increased aging is 
that more care and prescription drugs are likely to be required. Ironically, despite the shorter lifespan 
that can accompany chronic diseases, lifetime drug expenditures can exceed those of longer lived 
healthier populations. For example, Rappange et al. [86] found that lifetime drug costs among the 
obese were higher than those of a healthier-living cohort despite the former group having a shorter life 
expectancy. Asche et al. [87] compared the all-cause health care costs of newly diagnosed  
patients (1,411) with multiple sclerosis (MS) against a “healthy” comparison group (7,055) for a  
12-month period. They found that the MS group costs were significantly elevated over those of the 
comparison group ($18, 829 vs. $4,028).  
2.7. Misregulated Inflammation Is the Root of Most Chronic Diseases 
Chronic inflammation as a result of unresolved acute inflammation has been suggested as a 
unifying basis for most, if not all, chronic diseases of today. It is the disorder that best predicts chronic 
diseases [2,88−90]. In fact, most chronic diseases are dependent upon chronic inflammation as a key 
factor in their development and/or maintenance [91]. Additionally, Prasad et al. [92] argue that all risk 
factors of chronic diseases up-regulate inflammation. The problem is so pervasive and extensive that 
Aller et al. [93] suggested that inflammation problems have the potential to exert an evolutionary impact. 
Gene-environment interactions are important in chronic inflammatory conditions [94], and this 
complements the idea that hypersusceptible subpopulations are likely to exist in which inflammatory 
dysfunction is more likely to occur under a set of early-life environmental conditions. Table 2 
emphasizes the significance of immune dysfunction and misregulated inflammation to chronic diseases 
by illustrating suggested biomarkers associated with each of several different types of chronic diseases. 
The common occurrence of innate immune markers associated with inflammation is striking.  
Chronic diseases linked with improper inflammation include: allergic and autoimmune conditions, 
various behavior disorders, sensory loss, sleep problems, frailty, depression [67], Parkinson's disease [95], 
as well as cardiovascular diseases, type 2 diabetes, chronic kidney disease, Alzheimer's disease and 
cancer [96]. In the latter case, cancer has emerged as one of the prime end-stage comorbidities of 
immune dysfunction and chronic inflammation. Immune problems resulting in chronic inflammation 
create an environment that elevates the risk of development and/or promotion of cancer [97,98]. This is 
consistent with the observed pattern that elevated cancer risk is associated with the tissue-specific 
targeting of chronic diseases involving inflamed tissues (e.g., lung cancer for asthma, skin cancer for 
psoriasis, and G.I. tract cancer for inflammatory bowel disease) [66].  
It has been suggested that chronic low level inflammation is involved with most forms of heart 
disease [99]. Atherosclerosis represents a prime example of an immune-mediated, chronic 
inflammatory disorder [100]. With atherosclerosis there is a progression through a timeline during which 
the transition from acute to chronic (or unresolved) inflammation results in inflammation-driven 
hypertension [101].  
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Table 2. Suggested Immune and/or Inflammatory Biomarkers of Chronic Diseases and Conditions. 
Disease/condition Suggested biomarkers Reference(s) 
Alzheimer’s disease Microglia and astrocyte proinflammatory cytokines IL-1, IL-6, 
TNF-alpha with inflammasome activation; Low M-CSF production 
by macrophages containing amyloid-B deposits; Altered TLR 
regulation 
[155−157] 
Asthma and 
respiratory allergies 
Altered signaling and/or levels of Toll-like receptors 2, 4, and 7; 
Increased IgE and/or IL-4 levels; Eosinophilic infiltration of tissues; 
Production of specific microRNAs 
[158−160] 
Atherosclerosis TLR 4, MyD88, and the inflammasome activation; Elevation of IL-
1 and IL-18, C-reactive protein; Lipoprotein-associated 
phospholipase A2 
[161,162] 
Autism Increased proinflammatory cytokines and abnormal innate immune 
responses 
[163] 
Chronic obstructive 
pulmonary disease 
Improper neutrophillic inflammation; Excessive ROS production; 
Excessive Th1 and Th17 activity; Impeded immune repair 
[164,165] 
Depression Increased proinflammatory cytokines IL-1, IL-6, TNF-alpha; 
Elevated cortisol 
[166,167] 
Food allergies Decline in TGF-beta producing T cells in the gut [168,169] 
Grave’s disease Dendritic cell polarization; impaired CD4+CD25+ regulatory T cell 
capacity 
[170] 
Hashimoto’s 
thyroiditis 
Decreased CD4+CD152+ T cells [171] 
Myalgic 
encephalomyelitis 
(Chronic Fatigue 
Syndrome) 
Elevated proinflammatory cytokines; Elevated serum neopterin and 
PMN-elastase; blunted T cell memory 
[172−174] 
Multiple sclerosis CD46 regulation; Activated microglial production of proinflammatory 
cytokines; Dysregulated Treg/Th17axis; Neuropilin-1 regulation 
[156,175−177]
Osteoporosis Urinary ratio of native (alpha) to isomerized (beta) CTX; 
Fragments of interalpha-trypsin-inhibitor heavy chain H4 precursor 
(ITIH4) 
[178,179] 
Parkinson’s disease Change in olfaction; Depression [180] 
Psoriasis IL-1F6 as well as upregulation of TNF-alpha, IL-17A, and IL-23 [181] 
Rheumatoid 
arthritis 
Macrophage overproduction of IL-1, IL-6 and TNF-alpha; CD4+ 
Th1- and Th17-driven inflammation; inflammasome activation; 
Autoantibodies to Fc portion of host immunoglobulins  
 
[182−184] 
Sarcoidosis A cytokine cascade of IL-1, IL-2, IL-6, IL-8, IL-12, IL-18, IFN-
gamma, and TNF-alpha promotes the recruitment, activation, and 
proliferation of mononuclear cells and a Th1-driven granulomatous 
response; Overabundance of activated CD4+ T cells; Altered 
dendritic cell maturation 
[164,185] 
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Table 2. Cont 
Disease/condition Suggested biomarkers Reference(s) 
Sjogren syndrome Enhanced production of type 1 interferons by dendritic and other 
cells; Increased oxidative stress; Autoantibodies against the RNA-
binding proteins SSA/SSB/RNP 
[186,187] 
Sleep disorders IL-6 levels in relation to other inflammation-regulating cytokines [188] 
Systemic sclerosis CD70 overexpression; Endothelial adhesion molecules; Soluble 
TNF-alpha receptor; Altered pulmonary surfactant production  
[189–191] 
Type 1 diabetes Macrophage overproduction of inflammatory cytokines and CD4+ 
Th1 subpopulation driven inflammation 
[192] 
A similar relationship exists between inflammation and metabolic disorders. Osborn and Olefsky [102] 
argue that chronic tissue inflammation mediated by macrophages is a critical link between the immune 
system and metabolic-based chronic diseases. Obesity is integrally linked with inflammation and 
altered immune status [90]. Age-related adiposity has been linked with chronic inflammation and, in 
particular, shifts in T cell and inflammatory macrophage populations in adipose tissue [103]. Even 
later, end-stage types of diseases such as chronic kidney disease are also predicted by earlier markers 
of inflammation [104,105].  
Not surprisingly, drugs designed to promote resolution of acute inflammation appear to show 
promise against multiple different chronic diseases. For example, resolvins are  a category of bioactive 
autacoids of enzymatically converted omega-3 polyunsaturated fatty acids. Because of their capacity to 
resolve misregulated inflammation, they are a promising drug candidate to treat a variety of  
chronic diseases [106].  
Improper inflammation in early life is a major factor in later life chronic diseases [107] and 
imbalances of innate immune cell populations have been suggested as a marker associated across many 
chronic diseases [108]. This is also telling since Netzer et al. [109] suggested that innate immune-
promoted reactive oxygen species production may be key to a loss of translational fidelity. The 
researchers proposed that loss of this fidelity and capacity to produce a wider spectrum of modified 
proteins may be an adaptive response of mammalian cells to undue stress. 
2.8. Human Avoidance of Misregulated Inflammation and Chronic Diseases 
If chronic diseases are a primary adverse health outcome of dysfunction that should be avoided, 
then the question becomes what is the cardinal sign that could be used to distinguish health from a life 
course filled with chronic diseases? We present the tenet that fulfillment of the human superorganism 
(human genome + microbiome) is pivotal for health. The detailed summation will vary from individual 
to individual. But it is clear that the human superorganism needs to form efficiently, effectively, and 
completely in the infant. As follows, we discuss this concept under the rubric of what we term: the 
completed self. Additionally, we consider the three major components that determine whether the 
immunologically-defined Completed Self can form: (1) useful epigenetic programming, (2) effective 
developmental immune maturation, and (3) complete microbiota colonization. The relationships 
among these three factors, misregulated inflammation, the Completed Self and interlinked patterns of 
comorbid chronic diseases are depicted in Figure 2. Significantly, Figure 1 show that these processes 
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occur during specific critical windows of development, and failure of critical maturational steps during 
these windows can compromise formation of the Completed Self and increase health risks across a lifetime. 
Figure 2. Early life interactions that disrupt formation of the Completed Self are suggested 
to be as a primary contributor to misregulated inflammation and risk of later-life chronic 
diseases. Reported comorbidities among selected chronic diseases and conditions are 
shown in this figure and are represented by the interconnecting lines among diseases. 
These comorbidities are extensive illustrating the extent to which much of human disease 
is interconnected and promoted by misregulated inflammation. For example, tissue-specific 
cancer is a later-life comorbidity of asthma (lung cancer), inflammatory bowel disease 
(gastrointestinal cancer) and psoriasis (skin cancer). Cardiovascular disease (e.g., 
atherosclerosis), depression, and frailty are common later-life comobidities. It is suggested 
that environmental interference with human superorganism formation corrupts a biological 
sign for later-life health. 
 
2.9. Three Key Factors That Affect Our Capacity for Self-Completion 
Three major processes and, in turn developmentally-timed vulnerabilities, exist relative to 
formation of the Completed Self. Figure 2 illustrates the risk to formation of the Completed Self that is 
associated with AEP, DIT and/or altered neonatal microbial colonization. 
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2.9.1. Altered Epigenetic Programming (AEP) Across Generations 
One key factor that can lead to misregulated inflammation and elevated risk of chronic diseases is 
AEP. Environmentally-induced epigenetic programming may reflect in utero or neonatal 
environmental insults similar to DIT (discussed in the following sections) or alternatively, it may be 
expressed across several generations and not reflect direct exposure and immune disruption. 
Regardless of the generations exposed and affected, an alteration in gene expression patterns that 
produces inappropriate responses to host challenge and misregulated inflammation appears likely to 
elevate the risk of one or more chronic diseases.  
Several examples have been reported in the literature with a focus on inflammation-associated 
cancer. The gene, cytidine deaminase, and its activation through epigenetic alterations cause alterations 
in immunoglobulins via changes in somatic events. Epigenetic activation of this gene has been linked 
with chronic inflammation and cancer [110]. Chiba et al. [111] discussed potential gene targets of EP 
that have been associated with inflammation-associated development of digestive tract cancers. 
Likewise, Rau et al. [112] identified methylation of the gene caudal homeobox factor 1 as a pathway 
leading to inflammation and intestinal metaplasia in humans. In the liver, Nishida and Goel [113] have 
reported that consistent gene methylation patterns and histone modification can be associated  
with hepatocarcinoma. 
Beyond cancer, Michael Skinner and colleagues [114] reported evidence that several classes of 
environmental toxicants produce F3 generation inherited DNA methylation patterns that were 
connected to a condition in rats modeling human polycystic ovary disease. This study provided a proof 
of concept for epigenetic transgenerational induction of chronic diseases. Diseases associated with 
several different tissues are connected to epigenetic changes. For example, a change in the cytokine 
gene producing interleukin-13 (IL-13) appears to be associated with allergic airway inflammation and 
remodeling [115]. Epigenetic reduction of histone deactylase 2 and its activity has been connected to 
oxidative stress, lung inflammation and increased risk of chronic obstructive pulmonary disease 
(COPD) [116]. Ospelt et al. [117] proposed that epigenetically produced inflammatory memory may 
be the key to risk of rheumatoid arthritis (RA). These authors suggested that a stable activation of 
synovial fibroblasts may provide the key step leading to improper inflammation and RA. Taken 
together, these studies suggest that epigenetic alteration affecting regulation of inflammation is likely 
to contribute to multigenerational risk of chronic diseases. 
2.9.2. Developmental Immunotoxicity (DIT) 
Influence of the environment on the developing immune system, indirectly via the mother during 
gestation or directly on the child, represents the second process that can significantly affect formation 
of the Completed Self and risk of chronic diseases. The developing immune system is vulnerable to a 
variety of environmental modulating agents that collectively have been discussed under the rubric of 
developmental immunotoxicity (DIT) [118]. The agents can include environmental chemicals, drugs, 
diet, pathogens, medical devices, and physical and psychological conditions including maternal and 
fetal stress [118].  
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When toxicants have been compared across ages, the developing immune system has been shown to 
be more sensitive than that of the fully-matured adult [119,120]. Increased sensitivity of the immune 
system in early life can take several forms: (1) lower exposure doses are required to induce 
immunotoxicity, (2) more persistent adverse immune effects exist across a lifetime, (3) a broader 
spectrum of adverse effects are produced and (4) an increased vulnerability to later-life, 
environmentally-triggered immunotoxicity becomes established. Age-based, increased vulnerability 
for the immune system is not the only concern. Depending upon the environmental factors involved 
and the parameters measured, developmental immune effects can represent the most sensitive 
measures of adverse outcomes [121]. A recent example in which DIT helped in the determination of 
safe levels can be found in the US EPA’s IRIS assessment of the widespread contaminant, 
trichloroethylene (TCE) [122]. 
 Importantly, DIT has the capacity to interfere with later-life, positive environmental factors and 
their role in continued maturation of the infant’s immune system [66]. This nullification effect of DIT 
for subsequent childhood environment-microbial enrichment has been shown in the case of risk of 
allergy. PCB exposure nullifies the otherwise beneficial effects of breastfeeding for risk of allergic 
sensitization [123] and pesticide exposure nullifies the benefits of growing up on a farm relative to risk 
of asthma [124]. As can occur with AEP, DIT can interfere with immune maturation and cause the 
blunting of otherwise beneficial effects of the microbiota. Theoretically, this can occur in two ways:  
(1) via direct interference with acceptance of commensal microbes as self or (2) via the limited 
capacity of the DIT-damaged neonatal immune system to respond to microbial pattern recognition 
signals for continued immune maturation. The end result is that DIT can block formation of the 
Completed Self or prevent us from fully benefitting from the presence of our microbial partners. 
The risk factors for DIT include environmental chemicals and drugs (e.g., environmental tobacco 
smoke, lead, mercury, polychlorinated biphenyls, paracetamol), maternal and neonatal diet, maternal 
and childhood infections, neonatal microbial exposures, birth delivery mode, and maternal and 
neonatal stress [118,125]. The determination of whether a specific environmental risk factor produces 
biologically-significant DIT is based on the genetics of the individual, prior exposure history, the 
exposure dose, the duration of exposure, the critical developmental windows of exposure, and  
gender [126,127]. A key point is that qualitatively different immunotoxic outcomes can occur 
depending only on the developmental timing of exposure. The implications are that environmental 
health risks for the immune system are both age- and gender specific and need to be treated as such in 
terms of safety evaluation and prevention. 
2.9.2.1. DIT and Misregulated Inflammation 
Recently, the role of DIT, innate immune cell development and risk of inappropriate inflammation 
were reviewed by Leifer and Dietert [128]. Major developmental immunotoxicants such as the heavy 
metals, lead, mercury, and cadmium and dioxin are known to impact innate immune cell responses to 
challenge and to promote inappropriate inflammatory responses leading to tissue damage. For 
example, Kasten-Jolly et al. [129] found that developmental exposure of mice to lead targeted changes 
in innate immune cell gene expression as a major outcome. They further argued that the multi-system 
adverse effects following developmental lead exposure could be related to systemic inflammation. 
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Hogaboam et al. [130] reported that developmental exposure of mice to 2,3,7,8-tetrachloro-dibenzo-p-
dioxin causes the offspring to mount an excessive neutrophil-driven inflammatory response in the lung 
in response to influenza challenge. These types of toxicant-induced misregulation of inflammation are 
likely contributors to chronic diseases. Finally, Dietert [131] reviewed the widespread capacity of 
endocrine disrupting chemicals to disrupt immune maturation and produce misregulated inflammation 
following early life exposures. 
2.9.2.2. DIT and Infectious Agents Can Combined to Initiate Chronic Diseases 
Among the early-life environmental risk factors for immune-based disease, some of these factors 
such as environmental toxicants appear to cause immune dysfunction and disease. In contrast, other 
environmental risk factors such as infectious agents (e.g., respiratory viruses) may act as triggers of 
disease rather than necessarily serving as causes. For example, certain infections in children can 
produce tissue damaging immune responses from an already maturationally-dysfunctional childhood 
immune system [132].  
In addition to allergic and autoimmune diseases, neurodegenerative diseases appear to have a 
similar association to infections. Deleidi and Isacson [133] suggested that triggers of inflammation 
such as viral infections are critical in the initiation of many neurodegenerative chronic diseases. These 
authors stress the importance of activation of microglia and production of proinflammatory cytokines 
prior to the development of Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. 
2.9.3. Altered Neonatal Microbial Colonization 
At birth most mammals, including humans, have yet to encounter microorganisms. That will change 
rapidly and the subsequent interactions define the playing field for what is self and then tolerated vs. 
what is a danger and needing to be attacked. As described by Vassallo and Walker [134], colonization of 
the infant’s gut with microbes is a critical step in microbe-host programming that results in a balanced 
mutualism, which can greatly impact the later-life health and risk of disease in the individual. 
Comparison of the number of microbial cells to mammalian cells in humans is staggering with microbes 
outnumbering the latter by at least a magnitude [135]. Our commensal microbes are not an after-thought. 
Once we are separated from our mother’s body, we become significantly microbial. These microbes also 
play a critical role in necessary further maturation and programming of the developing immune  
system [136]. Martin et al. [19] stressed that while environmental microbes had been viewed as 
significant in postnatal immune maturation, it is more likely that commensal microorganisms (the 
microbiota) are the primary drivers of immune maturation. In his review, Oller [6] discussed the 
importance of the gut microbiota and, in particular, how an individual’s own genetic background can 
shape the composition of the microbiota. This is a very significant point in that different individuals are 
likely to differ in the exact microbial partners that help form the Completed Self. 
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3. Discussion 
3.1. DIT, Missing Microbes, and Future Health 
Beyond this early-life co-dependency, perinatal immune status and microbiota status fit together to 
ultimately affect the risk of chronic inflammation and later-life disease [137]. De Palma et al. [138] 
described studies in which the specific microbiota composition of the gut affected dendritic cell 
maturation and were shown to either lead to normal and effective functional outcomes or alternatively, 
to immune dysfunction. Substitution of probiotic Bifidobacterium with enterobacteria was shown to 
drive dendritic cell maturation toward a celiac disease-like inflammatory phenotype. 
There are similarities in outcomes between DIT and impaired microbiota formation. These can be 
seen in the lack of effective immune homeostasis and in an elevated risk of specific immune-
inflammation-driven chronic diseases. For example, a reduced diversity of gut microbiota in an infant 
has been reported to elevate the risk of allergic disease [139]. Remarkably, similar outcomes have been 
reported for DIT-associated perinatal exposures to marine pollutants [123], paracetamol [140], and not 
surprisingly, antibiotics [141]. However, in the case of perinatal exposure to antibiotics it is unclear 
whether the developmental target for later-life disorder and disease is the microbiome, the developing 
immune system, or both. 
Abt et al. [142] examined the effects of antibiotic depletion of commensal bacteria in mice on 
immune cell development. They found that both innate and adaptive immunity were impaired with the 
absence of commensals and that innate immune cells such as macrophages were unable to support 
antiviral host defense. They argue that the microbiota help to establish an activation threshold of the 
innate immune system and that is needed for antiviral immunity [142]. Additionally, commensal 
bacteria are reported to be able to shift the course of hematopoietic development and, thereby, affect 
the sensitivity toward allergic inflammation [143]. 
3.2. Reducing the Risk of Chronic Diseases and Conditions: Prevention and Proactive Strategies 
Not surprisingly, prevention of chronic diseases by keeping people out of harm’s way of 
environmental hazards has been emphasized as the most effective solution to the ongoing crisis [144]. 
In a recent review, Sears and Genius [145] describe the public health process for addressing chronic 
diseases that can include risk recognition and chemical assessment then exposure reduction, 
remediation, monitoring, and finally, avoidance. One of the reasons to focus on avoiding problems 
early in life is the previously discussed interlinked patterns of chronic diseases. Once an individual 
receives an initial diagnosis of a chronic disease or condition (often during childhood), the probability 
is that additional chronic diseases will emerge later in that individual’s life [73]. Therefore, prevention 
can be viewed as not simply reducing the risk of one chronic disease in an individual but rather of 
multiple debilitating conditions over the course of a lifetime.  
However, where the current paradigm leads is not simply toward prevention of environmental 
insult. Instead, there is a broader focus on the Completed Self as the best indicator for a lifetime of 
optimized health. This broader focus would include both: (1) protection of host self-recognition and 
defenses (i.e., the immune system) across generations and (2) proactive strategies to ensure that 
newborns are able to incorporate their microbiome in a complete, efficient and timely manner. 
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Individuals and their specific tailored-microbiological components will vary. However, it seems likely 
that measures reflecting the status of human superorganism formation will be on the horizon and can 
be used to guide a holistic approach to children’s health 
4. Conclusions  
We discussed the utility of an immunologically-defined sign, formation of the Completed Self or 
human superorganism, whose integrity is essential for a healthful life. Three major components affect 
the formation and integrity of this sign: useful epigenetic programming, effective immune 
development, and complete microbiota acquisition. Because the Completed Self needs to form in the 
neonate, prenatal and perinatal protection of this process is paramount to reduce the risk of chronic 
diseases, lower healthcare costs and improve quality of life. 
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